Table 2. Patient characteristics.
| Characteristics | ACEI/ARB (n=27) | Non-ACEI/ARB with HT (n=25) | Non-HT (n=103) | P-value |
|---|---|---|---|---|
| Median age, years (range) | 71 (53–87) | 73 (56–88) | 63 (41–89) | <0.001 |
| Gender (male/female) | 15/12 | 11/14 | 58/45 | 0.538 |
| PS | 0.621 | |||
| 0 | 14 | 11 | 40 | |
| 1 | 9 | 13 | 47 | |
| 2 | 4 | 1 | 14 | |
| 3 | 0 | 0 | 2 | |
| Location | 0.355 | |||
| Head | 12 | 16 | 53 | |
| Body/tail | 15 | 9 | 50 | |
| Stage | 0.668 | |||
| Locally advanced | 12 | 10 | 40 | |
| Metastatic | 15 | 15 | 63 | |
| Site of metastasis, n (%) | ||||
| Liver | 10 (37.0%) | 12 (48.0%) | 46 (44.7%) | 0.942 |
| Lung | 1 (3.7%) | 3 (12.0%) | 13 (12.6%) | 0.473 |
| Lymph node | 13 (48.2%) | 12 (48.0%) | 50 (48.5%) | 1.000 |
| Peritoneum | 3 (11.1%) | 1 (4.0%) | 15 (14.6%) | 0.412 |
| Median CEA, ng ml−1 (range) | 4.0 (0.8–120.2) | 6.1 (2.4–2964.3) | 5.7 (1–2756.9) | 0.201 |
| Median CA19-9, U ml−1 (range) | 490 (1–145600) | 421 (1–102100) | 324 (1–182600) | 0.788 |
| Hypertension | 27 | 25 | 0 | <0.001 |
Abbreviations: ACEI=angiotensin I-converting enzyme inhibitor; ARB=angiotensin II type-1 receptor blocker; CA19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; HT=hypertension; PS=performance status.